/DVAX
DVAX Stock - Dynavax Technologies Corporation
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$10.86-0.09%
$0.01 (-0.09%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.53
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+190.1%upside
Target: $31.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DVAX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$10.75 – $10.97
TARGET (TP)$31.50
STOP LOSS$9.99
RISK/REWARD1:23.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.89
52W High$14.63
52W Low$9.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $277.25M | $232.28M | $722.68M | $439.44M | $46.55M |
| Gross Profit | $227.80M | $182.12M | $460.53M | $265.87M | $32.64M |
| Gross Margin | 82.2% | 78.4% | 63.7% | 60.5% | 70.1% |
| Operating Income | $-4,122,000 | $-37,028,000 | $283.52M | $134.49M | $-75,222,000 |
| Net Income | $27.31M | $-6,389,000 | $293.16M | $76.71M | $-75,240,000 |
| Net Margin | 9.9% | -2.8% | 40.6% | 17.5% | -161.6% |
| EPS | $0.21 | $-0.05 | $2.32 | $0.62 | $-0.75 |
Company Overview
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
1
33%
Sell / Underperform
1
33%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$18
Average Target
↑ 65.7% Upside
Now
$12
Low
$18
Average
$22
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 11th 2025 | Goldman | Downgrade | Sell | $12← $15 |
| February 1st 2024 | Goldman | Initiation | Neutral | $20 |
| September 27th 2022 | JMP Securities | Initiation | Mkt Outperform | $22 |
Earnings History & Surprises
DVAXBeat Rate
67%
Last 18 quarters
Avg Surprise
+56.7%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$0.21
Q4 2025
EPS Surprise History
Q1 24
+100.0%
$0.00vs$0.00
Q2 24
-40.0%
$-0.07vs$-0.05
Q3 24
+33.3%
$0.08vs$0.06
Q4 24
+9.1%
$0.12vs$0.11
Q1 25
0.0%
$0.05vs$0.05
Q2 25
-466.7%
$-0.11vs$0.03
Q3 25
+16.7%
$0.14vs$0.12
Q4 25
+50.0%
$0.21vs$0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.14 | $0.21 | +50.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.12 | $0.14 | +16.7% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.03 | $-0.11 | -466.7% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $0.05 | $0.05 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $0.11 | $0.12 | +9.1% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.06 | $0.08 | +33.3% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $0.00 | $0.00 | +100.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.01 | $0.10 | +766.6% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.09 | $0.03 | +133.3% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-0.12 | $-0.19 | -58.3% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $0.43 | $0.45 | +4.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.33 | $0.43 | +30.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.22 | $0.87 | +295.5% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $0.24 | $0.22 | -8.3% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $0.69 | $0.55 | -20.3% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $0.05 | $0.06 | +20.0% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $0.01 | $0.02 | +155.1% | ✓ BEAT |
Latest News
Dynavax Is Providing FY25 Financial Guidance, Based On Its Current Operating Plan; HEPLISAV-B Net Product Revenue Is Expected In The Range Of $315M-$325M; Adjusted EBITDA Is Expected To Be At Least $80M, An Increase Compared To The Prior Guidance Of At Least $75M
📈 PositiveBenzinga•Nov 5, 2025, 09:03 PM
Dynavax Technologies Collaborates With Vaxart To Develop, Commercialize COVID-19 Vaccines On Vaxart's Platform; Dynavax Will Pay $25M Upfront License Fee, $5M Equity Investment In Vaxart
📈 PositiveBenzinga•Nov 5, 2025, 09:02 PM•Also:
Dynavax Announces New $100M Share Repurchase Program
📈 PositiveBenzinga•Nov 5, 2025, 09:02 PM
Dynavax Technologies Q3 EPS $0.21 Beats $0.12 Estimate, Sales $94.876M Beat $94.003M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:02 PM
Dynavax Reports Phase 1/2 Data For Shingles Vaccine Z-1018, Begins Head-To-Head Trial vs. Shingrix In Adults 70+
📈 PositiveBenzinga•Oct 21, 2025, 08:23 PM
Dynavax Presents Topline Data From Part 1 Of Phase 1/2 Trial For Shingles Vaccine Candidate At IDWeek 2025; Announces Initiation Of Part 2 Of Trial
📈 PositiveBenzinga•Oct 21, 2025, 08:03 PM
Shares of vaccine companies are trading lower following a Daily Beast report suggesting that President Trump and Health and Human Services Robert F. Kennedy, Jr. will ban Covid-19 vaccines "within months.
📉 NegativeBenzinga•Aug 25, 2025, 05:50 PM•Also: , ,
JMP Securities Reiterates Market Outperform on Dynavax Technologies, Maintains $32 Price Target
📈 PositiveBenzinga•Aug 22, 2025, 12:48 PM
Dynavax says shingles shot performed on par with GSK's Shingrix in Phase 1/2 trial
📈 PositiveSeeking Alpha•Aug 21, 2025, 01:06 PM•Also:
Dynavax Technologies shares are trading higher after the company announced its shingles vaccine candidate Z-1018 has shown efficacy in its Phase 1/2 trial.
📈 PositiveBenzinga•Aug 21, 2025, 12:53 PM
Dynavax's Shingles Vaccine Candidate Z-1018 Shows Comparable Immune Response To Shingrix With Fewer Side Effects; Advancing To Next Trial Phase In 2025
📈 PositiveBenzinga•Aug 21, 2025, 12:11 PM
Frequently Asked Questions about DVAX
What is DVAX's current stock price?
Dynavax Technologies Corporation (DVAX) is currently trading at $10.86 per share. The stock has moved -0.09% today.
What is the analyst price target for DVAX?
The average analyst price target for DVAX is $31.50, based on 1 analyst.
What sector is Dynavax Technologies Corporation in?
Dynavax Technologies Corporation operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is DVAX's market cap?
Dynavax Technologies Corporation has a market capitalization of $1.28 billion, making it a small-cap company.
Does DVAX pay dividends?
No, Dynavax Technologies Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMPH
Amphastar Pharmaceuticals, Inc.
$26.60
Mkt Cap: $1.2B
BBNX
Beta Bionics, Inc.
$29.25
Mkt Cap: $1.3B
COLL
Collegium Pharmaceutical, Inc.
$48.88
Mkt Cap: $1.5B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
EVO
Evotec SE
$2.95
Mkt Cap: $1.0B
HROW
Harrow Health, Inc.
$46.40
Mkt Cap: $1.7B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
PCRX
Pacira BioSciences, Inc.
$26.35
Mkt Cap: $1.2B
PLSE
Pulse Biosciences, Inc.
$15.26
Mkt Cap: $1.0B
STAA
STAAR Surgical Company
$25.14
Mkt Cap: $1.2B
Explore stocks similar to DVAX for comparison